SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
The campaign builds on the three-year partnership unveiled earlier this season
Board approves five-year appointment, subject to shareholder nod through postal ballot
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The presentations underscore the company’s deep expertise in dermatology and immunology
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Company to launch product after the expiry of semaglutide patent in India
Subscribe To Our Newsletter & Stay Updated
